Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020672 (hypothermia)
 17,327 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Temporary cessation of blood flow is a necessary aid for certain complex neurosurgical and cardiovascular procedures, and hypothermia is often used to help protect against the deleterious effects of ischemia and anoxia. In an attempt to protect cellular integrity during ultraprofound hypothermia (< 10 degrees C) and complete blood substitution, two new crystalloid-colloid blood substitutes (Hypothermosol-maintenance [HTS-M] and Hypothermosol-purge [HTS-P]) have been evaluated. Using extracorporeal bypass, 14 dogs were totally exsanguinated during cooling using the HTS-P solution, then perfused (40-85 ml/kg/min; mean arterial blood pressure = 25-40 mmHg) with either TS-M (Group I, n = 11), or with HTS-P as controls (Group II, n = 3) for 3 hr at 7 degrees C. During warming, the dogs were autotransfused and observed neurologically and biochemically during recovery. All dogs in Group I recovered and eight have survived long term (12-80 weeks) without apparent neurologic deficits. In contrast, dogs in Group II were more difficult to revive (cardiac resuscitation); two survived long term with delayed neurologic recovery. Evaluation of biochemical parameters showed only a transient and inconsequential elevation in enzymes (e.g., brain, liver, and heart) in Group I compared with the markedly greater elevations in Group II. The faster neurologic recovery of dogs treated with the "intracellular" maintenance solution supports the biochemical data showing the benefits of this type of blood substitute for extending the safe limits of hypothermic cardiac arrest to beyond 3 hr.
 ...
PMID:Asanguineous whole body perfusion with a new intracellular acellular solution and ultraprofound hypothermia provides cellular protection during 3.5 hours of cardiac arrest in a canine model. 855 38

Hepatocyte transplantation is a promising alternative therapy for the treatment of hepatic failure, hepatocellular deficiency, and genetic metabolic disorders. Hypothermic preservation of isolated human hepatocytes is potentially a simple and convenient strategy to provide on-demand hepatocytes in sufficient quantity and of the quality required for biotherapy. In this study, first we assessed how cold storage in three clinically safe preservative solutions (UW, HTS-FRS, and IGL-1) affects the viability and in vitro functionality of human hepatocytes. Then we evaluated whether such cold-preserved human hepatocytes could engraft and repopulate damaged livers in a mouse model of liver failure. Human hepatocytes showed comparable viabilities after cold preservation in the three solutions. The ability of fresh and cold-stored hepatocytes to attach to a collagen substratum and to synthesize and secrete albumin, coagulation factor VII, and urea in the medium after 3 days in culture was also equally preserved. Cold-stored hepatocytes were then transplanted in the spleen of immunodeficient mice previously infected with adenoviruses containing a thymidine kinase construct and treated with a single dose of ganciclovir to induce liver injury. Engraftment and liver repopulation were monitored over time by measuring the blood level of human albumin and by assessing the expression of specific human hepatic mRNAs and proteins in the recipient livers by RT-PCR and immunohistochemistry, respectively. Our findings show that cold-stored human hepatocytes in IGL-1 and HTS-FRS preservative solutions can survive, engraft, and proliferate in a damaged mouse liver. These results demonstrate the usefulness of human hepatocyte hypothermic preservation for cell transplantation.
...
PMID:Cold Preservation of Human Adult Hepatocytes for Liver Cell Therapy. 2562 96